Publications
Alvarez-Breckenridge C, Anderson KG, Correia AL, Demehri S, Dinh HQ, Dixon KO, Dunn GP, Evgin L, Goc J, Good Z, Hacohen N, Han P, Hanč P, Hickey J, Kersten K, Liu BC, Buque A, Miao Y', Milner JJ, Pritykin Y, Pucci F, Scharping NE, Sudmeier L, Wang Y, Wieland A, Williams MM. Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium. Cancer Immunol Res. 2023 Oct 31;:OF1-OF7. doi: 10.1158/2326-6066.CIR-23-0522. [Epub ahead of print] PubMed PMID: 37906619.
Mikula AL, Pennington Z, Lakomkin N, Prablek M, Amini B, Karim SM, Patel SS, Lubelski D, Sciubba DM, Alvarez-Breckenridge C, North RY, Tatsui CE, Bydon M, Fogelson JL, Elder BD, Krauss WE, Bird JE, Rose PS, Clarke MJ, Rhines LD. Risk factors for sacral fracture following en bloc chordoma resection. J Neurosurg Spine. 2023 Nov 1;39(5):611-617. doi: 10.3171/2023.3.SPINE221108. Print 2023 Nov 1. PubMed PMID: 37060308.
Ledbetter D, de Almeida R, Wu X, Naveh A, Patel CB, Gonzalez Q, Beckham TH, North R, Rhines L, Li J, Ghia A, Aten D, Tatsui C, Alvarez-Breckenridge C. Tumor treating fields suppress tumor cell growth and neurologic decline in models of spine metastases. JCI Insight. 2024 Mar 21;. doi: 10.1172/jci.insight.176962. [Epub ahead of print] PubMed PMID: 38512420.
Shanker MD, Cavazos AP, Li J, Beckham TH, Yeboa DN, Wang C, McAleer MF, Briere TM, Amini B, Tatsui CE, North RY, Alvarez-Breckenridge CA, Cezayirli PC, Rhines LD, Ghia AJ, Bishop AJ. Definitive single fraction spine stereotactic radiosurgery for metastatic sarcoma: Simultaneous integrated boost is associated with high tumor control and low vertebral fracture risk. Radiother Oncol. 2024 Apr;193:110119. doi: 10.1016/j.radonc.2024.110119. Epub 2024 Feb 3. PubMed PMID: 38311030.
Nayyar N, de Sauvage MA, Chuprin J, Sullivan EM, Singh M, Torrini C, Zhang BS, Bandyopadhyay S, Daniels KA, Alvarez-Breckenridge C, Dahal A, Brehm MA, Brastianos PK. CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis. Clin Cancer Res. 2023 Aug 23:CCR-23-0433. doi: 10.1158/1078-0432.CCR-23-0433. Online ahead of print. PMID: 37611074.
Wu X, Alvarez-Breckenridge C. Moving the Pendulum for Glioblastoma Treatment: One Injection at a Time. Oncologist. 2023 Aug 3;28(8):651-653. doi: 10.1093/oncolo/oyad104. PMID: 37130338.
Alvarez-Breckenridge C, de Almeida R, Haider A, Muir M, Bird J, North R, Rhines L, Tatsui C. Carbon Fiber-Reinforced Polyetheretherketone Spinal Implants for Treatment of Spinal Tumors: Perceived Advantages and Limitations. Neurospine. 2023 Mar;20(1):317-326. doi: 10.14245/ns.2244920.460. Epub 2023 Mar 31. PMID: 37016879.
Fomchenko EI, Bayley JC, Alvarez-Breckenridge C, Rhines LD, Tatsui CE. Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. Neurospine. 2022 Dec;19(4):978-993. doi: 10.14245/ns.2244290.145. Epub 2022 Dec 31. PubMed PMID: 36597635; PubMed Central PMCID: PMC9816609.
Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 Oct 1;45(8):374-378. doi: 10.1097/CJI.0000000000000431. Epub 2022 Aug 4. PubMed PMID: 35943386; PubMed Central PMCID: PMC9452485.
Rubino F, Alvarez-Breckenridge C, Akdemir K, Conley AP, Bishop AJ, Wang WL, Lazar AJ, Rhines LD, DeMonte F, Raza SM. Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels. Front Oncol. 2022;12:997506. doi: 10.3389/fonc.2022.997506. eCollection 2022. PubMed PMID: 36248987; PubMed Central PMCID: PMC9557284.
Alvarez-Breckenridge C, Markson SC, Stocking JH, Nayyar N, Lastrapes M, Strickland MR, Kim AE, de Sauvage M, Dahal A, Larson JM, Mora JL, Navia AW, Klein RH, Kuter BM, Gill CM, Bertalan M, Shaw B, Kaplan A, Subramanian M, Jain A, Kumar S, Danish H, White M, Shahid O, Pauken KE, Miller BC, Frederick DT, Hebert C, Shaw M, Martinez-Lage M, Frosch M, Wang N, Gerstner E, Nahed BV, Curry WT, Carter B, Cahill DP, Boland GM, Izar B, Davies MA, Sharpe AH, Suvà ML, Sullivan RJ, Brastianos PK, Carter SL. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunol Res. 2022 Aug 3;10(8):996-1012. doi: 10.1158/2326-6066.CIR-21-0870. PubMed PMID: 35706413.
Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004935. PubMed PMID: 35902132; PubMed Central PMCID: PMC9341188.
Strickland MR, Alvarez-Breckenridge C, Gainor JF, Brastianos PK. Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity. Cancer Discov. 2022 May 2;12(5):1199-1216. doi: 10.1158/2159-8290.CD-21-0976. Review. PubMed PMID: 35394521.
Alvarez-Breckenridge C, Remon J, Piña Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, Brastianos PK. Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-19. doi: 10.1200/EDBK_352320. PubMed PMID: 35522917.
Prakadan SM, Alvarez-Breckenridge CA, Markson SC, Kim AE, Klein RH, Nayyar N, Navia AW, Kuter BM, Kolb KE, Bihun I, Mora JL, Bertalan MS, Shaw B, White M, Kaplan A, Stocking JH, Wadsworth MH 2nd, Lee EQ, Chukwueke U, Wang N, Subramanian M, Rotem D, Cahill DP, Adalsteinsson VA, Miller JW, Sullivan RJ, Carter SL, Brastianos PK, Shalek AK. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat Commun. 2021 Oct 12;12(1):5955. doi: 10.1038/s41467-021-25860-5. PubMed PMID: 34642316; PubMed Central PMCID: PMC8511044.
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, Sahu A, Mei S, Miao B, Sharova T, Alvarez-Breckenridge C, Stocking JH, Kim T, Fadden R, Lawrence D, Hoang MP, Cahill DP, Malehmir M, Nowak MA, Brastianos PK, Lian CG, Ruppin E, Izar B, Herlyn M, Van Allen EM, Nathanson K, Flaherty KT, Sullivan RJ, Kellis M, Sorger PK, Boland GM. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 Jun;27(6):985-992. doi: 10.1038/s41591-021-01331-8. Epub 2021 May 3. PubMed PMID: 33941922; PubMed Central PMCID: PMC8474080.
Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug;26(8):1280-1284. doi: 10.1038/s41591-020-0918-0. Epub 2020 Jun 2. PubMed PMID: 32483359.
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, Kuter B, Kaufman B, Strickland MR, Martinez-Gutierrez JC, Nagabhushan D, De Sauvage M, White MD, Castro BA, Hoang K, Kaneb A, Batchelor ED, Paek SH, Park SH, Martinez-Lage M, Berghoff AS, Merrill P, Gerstner ER, Batchelor TT, Frosch MP, Frazier RP, Borger DR, Iafrate AJ, Johnson BE, Santagata S, Preusser M, Cahill DP, Carter SL, Brastianos PK. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 Apr;52(4):371-377. doi: 10.1038/s41588-020-0592-7. Epub 2020 Mar 23. PubMed PMID: 32203465; PubMed Central PMCID: PMC7136154.
Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clin Cancer Res. 2019 Jun 1;25(11):3374-3383. doi: 10.1158/1078-0432.CCR-18-3049. Epub 2019 Feb 22. PubMed PMID: 30796030; PubMed Central PMCID: PMC6685218.
Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. Oncologist. 2019 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 22. PubMed PMID: 30796152; PubMed Central PMCID: PMC6516108.
Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017. PubMed PMID: 29872694; PubMed Central PMCID: PMC5871889.
Alvarez-Breckenridge CA, Choi BD, Suryadevara CM, Chiocca EA. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Curr Opin Virol. 2015 Aug;13:25-32. doi: 10.1016/j.coviro.2015.03.015. Epub 2015 Apr 4. Review. PubMed PMID: 25846988.
Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology. 2013 Apr 1;2(4):e23658. doi: 10.4161/onci.23658. PubMed PMID: 23734319; PubMed Central PMCID: PMC3654589.
Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012 Dec;18(12):1827-34. doi: 10.1038/nm.3013. Epub 2012 Nov 25. PubMed PMID: 23178246; PubMed Central PMCID: PMC3668784.
Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol. 2012 Apr;86(8):4566-77. doi: 10.1128/JVI.05545-11. Epub 2012 Feb 8. PubMed PMID: 22318143; PubMed Central PMCID: PMC3318659.